Studies of the platelet fibrinogen receptor in Glanzmann patients and uremic patients.
The purpose of the present study was to investigate the binding of fibrinogen to the platelet fibrinogen receptor. Glycoprotein (GP) IIIa was measured utilizing a fluorescein isothiocyanate (FITC)-labelled monoclonal antibody and an Ortho Spectrum III flow cytometer. The number of binding sites per platelet was calculated to be 30,200. Using this technique it appears possible not only to diagnose Glanzmann's thrombasthenia but also to identify carriers. In uremic patients a slightly lower number of GPIIIa molecules per cell than in control subjects was found. Treatment with erythropoietin had no significant effect on the expression of GPIIIa. Thrombin, and to a less extent ADP, increased the binding of FITC-conjugated fibrinogen to normal platelets but had no significant effect on the expression of GPIIIa.
Lindahl
T L
TL
Department of Clinical Chemistry, Akademiska Hospital, Uppsala, Sweden.
Lundahl
J
J
Netré
C
C
Egberg
N
N
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D001793:Blood Preservation; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D005434:Flow Cytometry; D006580:Genetic Carrier Screening; D006801:Humans; D008297:Male; D008875:Middle Aged; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism*; D013915:Thrombasthenia / Q000097:blood* / Q000235:genetics; D014511:Uremia / Q000097:blood* / Q000628:therapy
D010980:Platelet Membrane Glycoproteins; D004921:Erythropoietin; D005340:Fibrinogen